Sign in

    Jae Mom • Stifel

    Jae Mom is a Managing Director and Senior Analyst at Stifel, specializing in equity research with a focus on industrials, specifically covering companies such as Wabtec Corporation, Greenbrier, and Trinity Industries. With over a decade in equity research, Jae Mom has established a strong track record, frequently appearing in sector rankings and maintaining a high accuracy rate on industry stock calls, including above-average annualized returns for covered companies. Beginning his career at a major financial institution before joining Stifel in 2011, he has built a reputation for in-depth analysis and strategic investment recommendations. Jae Mom holds FINRA Series 7, 63, 86, and 87 certifications, reflecting a high level of professional accreditation and expertise in securities analysis.

    Jae Mom's questions to Clearside Biomedical Inc (CLSD) leadership

    Jae Mom's questions to Clearside Biomedical Inc (CLSD) leadership • Q1 2024

    Question

    Jae Mom, on behalf of Annabel Samimy, inquired about Clearside's preliminary thoughts on a Phase III trial design for CLS-AX, especially given competitors' superiority trials, and asked for an update on the FDA's progress in finalizing new clinical trial guidelines for wet AMD.

    Answer

    CEO George Lasezkay confirmed that internal planning for Phase III is underway with consultants. Chief Medical Officer Dr. Victor Chong added that a key differentiator for their trial design is the ability to retreat with their own drug. Regarding FDA guidelines, Dr. Chong noted the draft is still not finalized, and Mr. Lasezkay assured that Clearside will engage with the agency multiple times before finalizing any Phase III plans.

    Ask Fintool Equity Research AI